UniProt ID | HAT1_HUMAN | |
---|---|---|
UniProt AC | O14929 | |
Protein Name | Histone acetyltransferase type B catalytic subunit | |
Gene Name | HAT1 | |
Organism | Homo sapiens (Human). | |
Sequence Length | 419 | |
Subcellular Localization |
Isoform A: Nucleus matrix. Isoform B: Cytoplasm. Nucleus. Nucleus matrix. Nucleus, nucleoplasm. Localization is predominantly nuclear in normal cells. Treatment with hydrogen peroxide or ionizing radiation enhances nuclear localization through redis |
|
Protein Description | Acetylates soluble but not nucleosomal histone H4 at 'Lys-5' (H4K5ac) and 'Lys-12' (H4K12ac) and, to a lesser extent, acetylates histone H2A at 'Lys-5' (H2AK5ac). Has intrinsic substrate specificity that modifies lysine in recognition sequence GXGKXG. May be involved in nucleosome assembly during DNA replication and repair as part of the histone H3.1 and H3.3 complexes. May play a role in DNA repair in response to free radical damage.. | |
Protein Sequence | MAGFGAMEKFLVEYKSAVEKKLAEYKCNTNTAIELKLVRFPEDLENDIRTFFPEYTHQLFGDDETAFGYKGLKILLYYIAGSLSTMFRVEYASKVDENFDCVEADDVEGKIRQIIPPGFCTNTNDFLSLLEKEVDFKPFGTLLHTYSVLSPTGGENFTFQIYKADMTCRGFREYHERLQTFLMWFIETASFIDVDDERWHYFLVFEKYNKDGATLFATVGYMTVYNYYVYPDKTRPRVSQMLILTPFQGQGHGAQLLETVHRYYTEFPTVLDITAEDPSKSYVKLRDFVLVKLCQDLPCFSREKLMQGFNEDMAIEAQQKFKINKQHARRVYEILRLLVTDMSDAEQYRSYRLDIKRRLISPYKKKQRDLAKMRKCLRPEELTNQMNQIEISMQHEQLEESFQELVEDYRRVIERLAQE | |
Overview of Protein Modification Sites with Functional and Structural Information | ||
* ASA = Accessible Surface Area
Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
---|---|---|---|---|---|
2 | Acetylation | ------MAGFGAMEK ------CCCCCHHHH | 23.25 | 22223895 | |
3 | Ubiquitination | -----MAGFGAMEKF -----CCCCCHHHHH | 21.88 | 23000965 | |
9 | Acetylation | AGFGAMEKFLVEYKS CCCCHHHHHHHHHHH | 30.80 | 25953088 | |
9 | Ubiquitination | AGFGAMEKFLVEYKS CCCCHHHHHHHHHHH | 30.80 | 23000965 | |
14 | Ubiquitination | MEKFLVEYKSAVEKK HHHHHHHHHHHHHHH | 11.63 | 23000965 | |
15 | Sumoylation | EKFLVEYKSAVEKKL HHHHHHHHHHHHHHH | 20.59 | - | |
15 | 2-Hydroxyisobutyrylation | EKFLVEYKSAVEKKL HHHHHHHHHHHHHHH | 20.59 | - | |
15 | Succinylation | EKFLVEYKSAVEKKL HHHHHHHHHHHHHHH | 20.59 | 23954790 | |
15 | Neddylation | EKFLVEYKSAVEKKL HHHHHHHHHHHHHHH | 20.59 | 32015554 | |
15 | Acetylation | EKFLVEYKSAVEKKL HHHHHHHHHHHHHHH | 20.59 | 23954790 | |
15 | Ubiquitination | EKFLVEYKSAVEKKL HHHHHHHHHHHHHHH | 20.59 | 23000965 | |
20 | Ubiquitination | EYKSAVEKKLAEYKC HHHHHHHHHHHHCCC | 46.63 | 23000965 | |
21 | Ubiquitination | YKSAVEKKLAEYKCN HHHHHHHHHHHCCCC | 39.15 | 23000965 | |
26 | 2-Hydroxyisobutyrylation | EKKLAEYKCNTNTAI HHHHHHCCCCCCCCE | 16.71 | - | |
26 | Ubiquitination | EKKLAEYKCNTNTAI HHHHHHCCCCCCCCE | 16.71 | 21963094 | |
36 | Ubiquitination | TNTAIELKLVRFPED CCCCEEEEEEECCHH | 31.95 | 29967540 | |
50 | Phosphorylation | DLENDIRTFFPEYTH HHHHHHHHHCHHHHH | 29.93 | - | |
55 | Phosphorylation | IRTFFPEYTHQLFGD HHHHCHHHHHHHHCC | 15.12 | - | |
64 | Ubiquitination | HQLFGDDETAFGYKG HHHHCCCCCCCCHHH | 46.94 | 21890473 | |
67 | Ubiquitination | FGDDETAFGYKGLKI HCCCCCCCCHHHHHH | 16.73 | 22817900 | |
69 | Phosphorylation | DDETAFGYKGLKILL CCCCCCCHHHHHHHH | 8.74 | - | |
70 | Ubiquitination | DETAFGYKGLKILLY CCCCCCHHHHHHHHH | 59.14 | 21906983 | |
73 | Ubiquitination | AFGYKGLKILLYYIA CCCHHHHHHHHHHHH | 39.72 | 22817900 | |
77 | Phosphorylation | KGLKILLYYIAGSLS HHHHHHHHHHHHHHH | 6.86 | 21601212 | |
78 | Phosphorylation | GLKILLYYIAGSLST HHHHHHHHHHHHHHH | 5.58 | - | |
82 | Phosphorylation | LLYYIAGSLSTMFRV HHHHHHHHHHHHHHH | 15.32 | 21601212 | |
84 | Phosphorylation | YYIAGSLSTMFRVEY HHHHHHHHHHHHHHH | 21.37 | 21601212 | |
91 | Phosphorylation | STMFRVEYASKVDEN HHHHHHHHHCCCCCC | 17.20 | 29214152 | |
93 | Phosphorylation | MFRVEYASKVDENFD HHHHHHHCCCCCCCC | 32.10 | 21712546 | |
94 | Acetylation | FRVEYASKVDENFDC HHHHHHCCCCCCCCE | 45.60 | 26051181 | |
94 | Ubiquitination | FRVEYASKVDENFDC HHHHHHCCCCCCCCE | 45.60 | 33845483 | |
101 | Glutathionylation | KVDENFDCVEADDVE CCCCCCCEEECCCCC | 2.32 | 22555962 | |
104 | Ubiquitination | ENFDCVEADDVEGKI CCCCEEECCCCCCCE | 9.63 | 21963094 | |
110 | Ubiquitination | EADDVEGKIRQIIPP ECCCCCCCEEECCCC | 22.62 | 21906983 | |
128 | Phosphorylation | TNTNDFLSLLEKEVD CCCHHHHHHHHHCCC | 30.79 | 24719451 | |
152 | Phosphorylation | TYSVLSPTGGENFTF EEEEECCCCCCCEEE | 55.21 | 22210691 | |
158 | Phosphorylation | PTGGENFTFQIYKAD CCCCCCEEEEEEECC | 26.64 | 22210691 | |
190 | Phosphorylation | MWFIETASFIDVDDE HHHHHHCCEECCCCC | 30.10 | 28143904 | |
201 | Phosphorylation | VDDERWHYFLVFEKY CCCCCEEEEEEEEEC | 7.52 | 26437602 | |
245 | Phosphorylation | VSQMLILTPFQGQGH EEEEEEEECCCCCCH | 18.31 | - | |
274 | Ubiquitination | FPTVLDITAEDPSKS CCCEEEEECCCCCCC | 24.54 | 22817900 | |
278 | Ubiquitination | LDITAEDPSKSYVKL EEEECCCCCCCCEEH | 34.85 | 22817900 | |
280 | Ubiquitination | ITAEDPSKSYVKLRD EECCCCCCCCEEHHH | 51.71 | 21906983 | |
280 | Acetylation | ITAEDPSKSYVKLRD EECCCCCCCCEEHHH | 51.71 | 25953088 | |
284 | Ubiquitination | DPSKSYVKLRDFVLV CCCCCCEEHHHHHHH | 29.58 | 22817900 | |
286 | Methylation | SKSYVKLRDFVLVKL CCCCEEHHHHHHHHH | 29.60 | - | |
298 | Ubiquitination | VKLCQDLPCFSREKL HHHHCCCCCCCHHHH | 25.95 | 22817900 | |
301 | Phosphorylation | CQDLPCFSREKLMQG HCCCCCCCHHHHHCC | 46.37 | 20068231 | |
304 | Ubiquitination | LPCFSREKLMQGFNE CCCCCHHHHHCCCCH | 48.42 | 22817900 | |
304 | 2-Hydroxyisobutyrylation | LPCFSREKLMQGFNE CCCCCHHHHHCCCCH | 48.42 | - | |
306 | Sulfoxidation | CFSREKLMQGFNEDM CCCHHHHHCCCCHHH | 5.62 | 21406390 | |
314 | Ubiquitination | QGFNEDMAIEAQQKF CCCCHHHHHHHHHHH | 14.59 | 22817900 | |
316 | Ubiquitination | FNEDMAIEAQQKFKI CCHHHHHHHHHHHCC | 30.78 | 22817900 | |
319 | Ubiquitination | DMAIEAQQKFKINKQ HHHHHHHHHHCCCHH | 61.27 | 22817900 | |
320 | Ubiquitination | MAIEAQQKFKINKQH HHHHHHHHHCCCHHH | 36.22 | 21906983 | |
320 | 2-Hydroxyisobutyrylation | MAIEAQQKFKINKQH HHHHHHHHHCCCHHH | 36.22 | - | |
322 | Ubiquitination | IEAQQKFKINKQHAR HHHHHHHCCCHHHHH | 53.02 | 22817900 | |
325 | Ubiquitination | QQKFKINKQHARRVY HHHHCCCHHHHHHHH | 47.11 | 22817900 | |
342 | Sulfoxidation | LRLLVTDMSDAEQYR HHHHHCCCCHHHHHH | 2.59 | 30846556 | |
343 | Phosphorylation | RLLVTDMSDAEQYRS HHHHCCCCHHHHHHH | 36.16 | 30624053 | |
350 | Phosphorylation | SDAEQYRSYRLDIKR CHHHHHHHHHHHHHH | 15.07 | 22817900 | |
351 | Phosphorylation | DAEQYRSYRLDIKRR HHHHHHHHHHHHHHH | 13.24 | 22817900 | |
359 | Ubiquitination | RLDIKRRLISPYKKK HHHHHHHHCCCCHHH | 5.44 | 24816145 | |
361 | Phosphorylation | DIKRRLISPYKKKQR HHHHHHCCCCHHHHH | 27.11 | 22167270 | |
363 | Phosphorylation | KRRLISPYKKKQRDL HHHHCCCCHHHHHHH | 28.75 | 28152594 | |
364 | Acetylation | RRLISPYKKKQRDLA HHHCCCCHHHHHHHH | 57.80 | 25953088 | |
365 | Ubiquitination | RLISPYKKKQRDLAK HHCCCCHHHHHHHHH | 48.58 | 24816145 |
Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
---|---|---|---|---|---|---|
190 | S | Phosphorylation | Kinase | AMPKA1 | Q13131 | PSP |
Modified Location | Modified Residue | Modification | Function | Reference |
---|---|---|---|---|
190 | S | Phosphorylation |
| 28143904 |
* Distance = the distance between SAP position and PTM sites.
Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of HAT1_HUMAN !! |
Interacting Protein | Gene Name | Interaction Type | PPI Reference | Domain-Domain Interactions |
---|---|---|---|---|
ASF1B_HUMAN | ASF1B | physical | 20953179 | |
B2LA1_HUMAN | BCL2A1 | physical | 22615379 | |
THIK_HUMAN | ACAA1 | physical | 9427644 | |
H2A2C_HUMAN | HIST2H2AC | physical | 9427644 | |
RBBP7_HUMAN | RBBP7 | physical | 22939629 | |
RBBP7_HUMAN | RBBP7 | physical | 26186194 | |
CE051_HUMAN | C5orf51 | physical | 26344197 | |
SNF8_HUMAN | SNF8 | physical | 26344197 | |
TLN2_HUMAN | TLN2 | physical | 26344197 | |
RBBP7_HUMAN | RBBP7 | physical | 28514442 | |
ASF1A_HUMAN | ASF1A | physical | 28514442 | |
RBBP7_HUMAN | RBBP7 | physical | 28143904 |
Kegg Disease | ||||||
---|---|---|---|---|---|---|
There are no disease associations of PTM sites. | ||||||
OMIM Disease | ||||||
There are no disease associations of PTM sites. | ||||||
Kegg Drug | ||||||
There are no disease associations of PTM sites. | ||||||
DrugBank | ||||||
There are no disease associations of PTM sites. |
loading...
Acetylation | |
Reference | PubMed |
"Lys-N and trypsin cover complementary parts of the phosphoproteome ina refined SCX-based approach."; Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,Mohammed S.; Anal. Chem. 81:4493-4501(2009). Cited for: ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, AND MASS SPECTROMETRY. | |
Phosphorylation | |
Reference | PubMed |
"A quantitative atlas of mitotic phosphorylation."; Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,Elledge S.J., Gygi S.P.; Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-361, AND MASSSPECTROMETRY. | |
"Global, in vivo, and site-specific phosphorylation dynamics insignaling networks."; Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,Mann M.; Cell 127:635-648(2006). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-361, AND MASSSPECTROMETRY. |